TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneum... ( TAIPEI Taiwan Aug. 10 /Xinhua-- T...)

HOME >> MEDICINE >> TECHNOLOGY

TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)

Date:8/19/2007

TAIPEI, Taiwan, Aug. 10 /Xinhua-PRNewswire/ -- TaiGen Biotechnology Inc. announces the successful completion of patient recruitment for the global double-blind Phase II clinical trial of Nemonoxacin (TG-873870) for the treatment of adult community-acquired pneumonia (CAP). A total of 265 patients have been admitted to the trial. Completion of the trial data analysis is expected in the last quarter of 2007. In this trial, the effect of Nemonoxacin in comparison with levofloxacin, the leading quinolone on the market, is evaluated with both clinical and bacteriological success rates in treating adult patients with CAP.

"We are pleased with the efficient manner in which the 18 clinical centers have enrolled patients in the phase II study," said Dr. Ming Chu Hsu, Chairman and CEO of TaiGen. "Completing enrollment in this study shall keep us on track of our projected development timeline for this highly promising antibacterial for the treatments of resistant infection."

About TaiGen Biotechnology Co., LTD

TaiGen Biotechnology (http://www.taigenbiotech.com ) is a leading pharmaceutical company based in Taiwan and has a wholly-owned subsidiary in Beijing, China. The company is developing novel therapeutics to treat infectious diseases, diabetic complications and cancer for the worldwide market. TaiGen has a full capacity in new drug R&D and clinical development in China, Taiwan, US and other countries. Nemonoxacin, an once-a-day oral and IV antibacterial active against gram-positive and -negative pathogens and MRSA, will soon to enroll diabetic foot infection patients in a double-blind phase 2 trial. The company has first-in-class phase 1-ready drug candidates for treating critical limb ischemia and retinopathy/age-related macular degeneracy, and advanced preclinical candidates for chronic Hepatitis C virus infection and cancer.

Contact Information:

Stephen Ip, Ph.D.

SVP Gl
'/>"/>

SOURCE TaiGen Biotechnology Co., LTD

0

GOOD

Page: 1 2
Related medicine technology :

1. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
2. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
3. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
4. Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease
5. Prana Biotechnology Presents New Key Findings on PBT2
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ASCO Annual Meeting
7. Generex Biotechnology Vaccine Strategy Presented at International Conference in London
8. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at AUA Annual Meeting
9. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
10. Pegasys Study Authors Conclude that Patients Successfully Treated for Hepatitis C Can be Considered Cured
11. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials

Post Your Comments:

(Date:11/9/2009)...wire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Na... the third quarter ended September 30, 2009. ,,...on stockholders in the third quarter of 2009 of $3... loss allocable to common stockholders in the thir...hare, and a net loss allocable to common stockhold...

(Date:11/9/2009)...re/ -- Groundbreaking articles in current issues o...time explore, in depth, the emergence of cannabino...ers and its potential benefits for patients. ,,...gton authors, Sunil Aggarwal, PhD who is a member ...ram and who conducted the article,s research and G...

(Date:11/9/2009)...re/ -- Celling Technologies, a subsidiary of Spine...is, Inc. to research potential applications for ad... acquired the global rights in spine for Tissue Ge...nology in November of 2007. Replacing the prior a...lling Technologies to further research adipose tis...

[0] Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments [0] Medicinal Use of Marijuana: Past, Present and Future...A Fresh Look by Experts in the Field [0] Celling Technologies Signs Exclusive Agreement to Research and Develop Adipose Tissue Stem Cell Technology in Regenerative Medicine Institutes

...sdaq: TELK ) reported positive preclinical data f...ecule inhibitors of validated cancer targets,inclu...ented today at the,AACR-NCI-EORTC Conference on Mo...ncisco. Aurora kinases are enzymes that play a ke...-expressed in many human cancers, including breast...

...., a,privately held biopharmaceutical company deve...cular biomarker data demonstrating the overexpress...in in multiple cancers,including ovarian, breast a...ation of PARP overexpression in specific types of ...inical development of the company,s,pipeline of PA...

Other Medicine Technology:Telik Announces Preclinical Data Demonstrating Anti-Cancer Activity of Dual Inhibitors of Aurora Kinase and VEGFR2 2 BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types 2

Telik Announces Preclinical Data Demonstrating Anti-Cancer Activity of Dual Inhibitors of Aurora Kinase and VEGFR2 BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types

(Date:11/9/2009)... formation could boost self-esteem, researchers sa... Autistic children are more likely to have handwri...than those without autism, researchers say. , T...alf of the study participants had autism spectrum ...e normal range for perceptual reasoning on an IQ t...

(Date:11/9/2009)...v. 9 /PRNewswire-FirstCall/ - Hard To Treat Diseas...y that Novartis, a US$41 billion international hea..., H1N1 Vaccine partner, Zhejiang Tianyuan Bio-Phar... of Switzerland will begin a five-year, $1 billion...dramatically increase its investment in its China ...

(Date:11/9/2009)... New study highlights positive influence of sports... Rosemont, IL (Vocus) November 9, 2009 -- As...reases. Recent research has highlighted the import...revent these issues. However, a new study publishe...: A Multidisciplinary Approach reveals that there...

(Date:11/9/2009)...mes 2010 National Ambassador ,, WHITE PLAINS,...ffman of Weston, Fla., was born so early and with ...ot say whether he would survive -- or if he would ...d was named March of Dimes 2010 National Ambassado..."My first minutes of motherhood and I was complete...

(Date:11/9/2009)...people went from incapacitated to working again, ... Electrical stimulation of a certain area of the b...epression, say German researchers. , They impla...he brains of 10 people. This area of the brain is...e remember good experiences and puts them in a sta...

Breaking Medicine News(10 mins):Health News:Handwriting Skills May Lag in Kids With Autism 2 Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 2 Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 3 Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 4 Health News:High Impact Sports Participation May Improve Bone Mineral Density in Mature Athletes 2 Health News:Six-Year-Old Survivor Fights for Preemies Like Himself 2 Health News:Six-Year-Old Survivor Fights for Preemies Like Himself 3 Health News:Brain Stimulation May Ease Treatment-Resistant Depression 2

[0] Handwriting Skills May Lag in Kids With Autism [2] Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million [1] High Impact Sports Participation May Improve Bone Mineral Density in Mature Athletes [0] Six-Year-Old Survivor Fights for Preemies Like Himself [0] Brain Stimulation May Ease Treatment-Resistant Depression

...08 (Bronx, NY) Mutations in genes governing an im...gevity, scientists at the Albert Einstein College ...r research is described in the March 4 issue of th... longevity through their study that by now has rec...

... TORONTO, March 4 /PRNewswire/ - Affinium Pharmace...he dosing of healthy subjects in,a Phase I study o...om its,novel class of fatty acid biosyntheis inhib...1252 will provide patients,and their doctors a pot...

...se is available in Spanish . , The doctoral th...ped in the Departments of Department of Signal Th...ent of Surgery and its Specialties of the Univer...isition of Compound Action Potential records, carr...

..., March 4 Secretary of Health,Dr. Calvin B. Johns...maugh,Health System in Johnstown to discuss Govern...ealth insurance to hundreds of thousands of uninsu...chronic diseases such as diabetes and asthma, and ...

...cuss launch of the latest fleet golf car and the r...leader in,manufacturing execution systems (MES) fo...t will sponsor an IndustryWeek-hosted online event... place on Thursday, March 6, 2008 at 2:00 p.m. EST...

...project finds 90% of vision gains retained 1 year ...Day News) -- A new treatment for lazy eye shows pr...ers who found the therapy worked well in 20-year-o...developing countries, are diagnosed too late for c...

Other Medicine News:Health News:Einstein researchers discover gene mutations linked to longer lifespans 2 Health News:Affinium Pharmaceuticals, Ltd. Announces Initiation of a Phase I Clinical Trial for AFN-1252, its Novel Anti-staphylococcal Antibiotic 2 Health News:Design of a new system that improves hearing in patients who carry a cochlear implant 2 Health News:Design of a new system that improves hearing in patients who carry a cochlear implant 3 Health News:Health Secretary's Statewide Tour to Discuss Health Insurance for All Pennsylvanians Makes Stop in Cambria County 2 Health News:E-Z-GO and Visiprise to Participate in New Product Introduction Event with IndustryWeek 2 Health News:E-Z-GO and Visiprise to Participate in New Product Introduction Event with IndustryWeek 3 Health News:New Treatment for 'Lazy Eye' Shows Promise 2

Einstein researchers discover gene mutations linked to longer lifespans Affinium Pharmaceuticals, Ltd. Announces Initiation of a Phase I Clinical Trial for AFN-1252, its Novel Anti-staphylococcal Antibiotic Design of a new system that improves hearing in patients who carry a cochlear implant Health Secretary's Statewide Tour to Discuss Health Insurance for All Pennsylvanians Makes Stop in Cambria County E-Z-GO and Visiprise to Participate in New Product Introduction Event with IndustryWeek New Treatment for 'Lazy Eye' Shows Promise

Neuro-Cool™ Cool Head Wrap

...noWELL Mycoplasma Pneumoniae Antibody (IgG) Test i...the detection of clinically significant IgG antibo...nt human serum specimens. The test should not be u...ycoplasma Pneumoniae Antibody (IgM) Test and is no...

ImmunoDOT Mono M Test

...noWELL VCA IgG Test is an ELISA method for the qua... Virus viral capsid antigen (VCA) in human serum. ...other testing such as the EBV nuclear antigen (EBN...heterophile tests, the results can serve as an aid...

Medicine Products:

Neuro-Cool™ Cool Head Wrap ImmunoWELL Mycoplasma pneumoniae Antibody (IgG) Test ImmunoDOT Mono M Test ImmunoWELL EBV VCA IgG Test

TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneum...( TAIPEI Taiwan Aug. 10 /Xinhua-- T...),Health